Cargando…

Encouraging impact of doxycycline on early mortality in cardiac light chain (AL) amyloidosis

Detalles Bibliográficos
Autores principales:	Wechalekar, A D, Whelan, C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5380910/ https://www.ncbi.nlm.nih.gov/pubmed/28338670 http://dx.doi.org/10.1038/bcj.2017.26

Ejemplares similares

Early relapse is an adverse prognostic marker in systemic immunoglobulin light chain (AL) Amyloidosis
por: Ravichandran, Sriram, et al.
Publicado: (2022)

Light chain cardiac amyloidosis in a nonagenarian
por: Takahashi, Koji, et al.
Publicado: (2022)

Cardiac involvement in light chain amyloidosis: a case report
por: Li, Jing, et al.
Publicado: (2020)

(99m)Tc-DPD scintigraphy in immunoglobulin light chain (AL) cardiac amyloidosis
por: Quarta, Candida Cristina, et al.
Publicado: (2021)

Sequential heart and autologous stem cell transplantation for light-chain cardiac amyloidosis
por: Huh, Jin-Young, et al.
Publicado: (2017)

Cardiac biomarkers are prognostic in systemic light chain amyloidosis with no cardiac involvement by standard criteria
por: Sharpley, Faye A., et al.
Publicado: (2020)

Recognizing Pinch Purpura as the First Manifestation of Light-chain Amyloidosis
por: Öztürk, Erman, et al.
Publicado: (2018)

Extensive cardiac FDG uptake in a patient with AL amyloidosis
por: Hatipoglu, Suzan, et al.
Publicado: (2023)

Light chain amyloidosis associated with Waldenström macroglobulinemia: treatment and survival outcomes
por: Gustine, Joshua N., et al.
Publicado: (2022)

Light Chain (AL) Cardiac Amyloidosis: A Diagnostic Dilemma
por: Abdelazeem, Basel, et al.
Publicado: (2021)

Tracking Treatment Response in Cardiac Light-Chain Amyloidosis With Native T1 Mapping
por: Ioannou, Adam, et al.
Publicado: (2023)

Predictors of Mortality in Light Chain Cardiac Amyloidosis with Heart Failure
por: Tahir, Usman A., et al.
Publicado: (2019)

T1 mapping and survival in systemic light-chain amyloidosis
por: Banypersad, Sanjay M., et al.
Publicado: (2015)

A novel mass spectrometry method to identify the serum monoclonal light chain component in systemic light chain amyloidosis
por: Sharpley, Faye A., et al.
Publicado: (2019)

COVID-19 and Light Chain Amyloidosis: Correspondence
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Rationale and design of DUAL study: Doxycycline to Upgrade response in light chain (AL) amyloidosis (DUAL): A phase 2 pilot study of a two-pronged approach of prolonged doxycycline with plasma cell-directed therapy in the treatment of AL amyloidosis
por: D'Souza, Anita, et al.
Publicado: (2017)

Updates in Cardiac Amyloidosis: A Review
por: Banypersad, Sanjay M., et al.
Publicado: (2012)

Light Chain (AL) Amyloidosis: The Journey to Diagnosis
por: McCausland, Kristen L., et al.
Publicado: (2017)

Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis
por: Palladini, Giovanni, et al.
Publicado: (2021)

Immunoglobulin light chain amyloidosis presenting as Budd-Chiari syndrome
por: Ozercan, Mubin, et al.
Publicado: (2021)

Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib
por: Ravichandran, Sriram, et al.
Publicado: (2021)

Imaging modalities in early cardiac transthyretin amyloidosis: who is first?
por: Ney, Svenja, et al.
Publicado: (2022)

Seroconversion Rates After the Second COVID-19 Vaccination in Patients With Systemic Light Chain (AL) amyloidosis
por: Liebers, Nora, et al.
Publicado: (2022)

Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response
por: Grogan, Martha, et al.
Publicado: (2017)

Light chain (AL) amyloidosis: update on diagnosis and management
por: Rosenzweig, Michael, et al.
Publicado: (2011)

Lingual liability: macroglossia and dyspnoea as the harbinger of systemic AL (light-chain) cardiac amyloidosis
por: Williams, Michael Uncle, et al.
Publicado: (2018)

Heterogenous mutation spectrum and deregulated cellular pathways in aberrant plasma cells underline molecular pathology of light-chain amyloidosis
por: Chyra, Zuzana, et al.
Publicado: (2020)

Patterns of late gadolinium enhancement in 94 patients with AL or transthyretin cardiac amyloidosis
por: Dungu, Jason, et al.
Publicado: (2012)

Cardiovascular magnetic resonance in light-chain amyloidosis to guide treatment
por: Martinez-Naharro, Ana, et al.
Publicado: (2022)

Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis
por: Cuenca, Isabel, et al.
Publicado: (2020)

Physiology, Diagnosis and Treatment of Cardiac Light Chain Amyloidosis
por: Stelmach-Gołdyś, Agnieszka, et al.
Publicado: (2022)

Light Chain Amyloidosis
por: Milani, Paolo, et al.
Publicado: (2018)

AL Amyloidosis in a Patient with IgD Myeloma
por: Rafik, Hicham, et al.
Publicado: (2020)

Budd-Chiari Syndrome: An Unusual Complication of AL Amyloidosis
por: Tiryaki, Tarık Onur, et al.
Publicado: (2020)

Racial disparities in patients diagnosed with light chain (AL) amyloidosis
por: D’Souza, Anita, et al.
Publicado: (2021)

Differences in Immunoglobulin Light Chain Species Found in Urinary Exosomes in Light Chain Amyloidosis (AL)
por: Ramirez-Alvarado, Marina, et al.
Publicado: (2012)

Dexamethasone is associated with early deaths in light chain amyloidosis patients with severe cardiac involvement
por: Bézard, Mélanie, et al.
Publicado: (2021)

Doxycycline as an Alternative to Azithromycin in Elderly Patients
por: Malek, Alexandre Elias, et al.
Publicado: (2021)

Diagnostic and Therapeutic Strategy for Female Patients With Cardiac Amyloidosis
por: Imamura, Teruhiko, et al.
Publicado: (2021)

Need for encouraging translational research in India
por: Kelkar, Dhanashree, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_cvjgd6vth87g2cpd4nphs3e1ol